Abciximab

Therapeutic indications

Abciximab is indicated for:

Unstable angina

Population group: both men and women, only adults (18 years old or older)

Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 0.25mg/kg intravenous bolus

Percutaneous coronary intervention

Population group: both men and women, only adults (18 years old or older)

Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (PCI: balloon angioplasty, atherectomy, and stent).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 0.25mg/kg intravenous bolus

Contraindications

Abciximab is contraindicated in the following cases:

Thrombocytopenia

Thrombocytopenic disorder

Severe renal failure, dialysis

at least one of
Hemodialysis procedure

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Active internal bleeding

Bleeding

History of cerebrovascular accident within two years

H/O: CVA

Severe hepatic failure

Hepatic failure stage IV

Vasculitis

Vasculitis

Severe uncontrolled hypertension

Arteriovenous malformation, aneurysm

at least one of
Congenital arteriovenous malformation

Aneurysm

Recent (within two months) major surgery

Surgical procedure

Intracranial neoplasm

Intracranial tumour

Hypertensive retinopathy

Hypertensive retinopathy

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines